Over 30 years ago, Ferreira et al. [1] isolated a bradykininpotentiating peptide from the venom of a Central American viper. Shortly thereafter, Ondetti et al. [2] reported the isolation of an angiotensin-converting enzyme (ACE) inhibitor from the venom of the same snake. Erdös subsequently demonstrated that ACE and kininase II, which degrades bradykinin to inactive metabolites, are the same enzyme [3] , thus linking the renin-angiotensin system (RAS) and the kallikrein-kinin system (KKS).
RAS / KKS linkages
The RAS and KKS are linked at a number of levels. ACE not only converts Ang I to Ang II but also bradykinin to inactive metabolites [14] ; hence, ACE inhibitors increase circulating concentrations of bradykinin [15] . Recent evidence suggests that ACE inhibitors also potentiate the effects of bradykinin via direct effects at the bradykinin B 2 receptor [16, 17] . For example, Benzing et al. [18] demonstrated that ramiprilat, a tissue-specific ACE inhibitor, inhibited the desensitization of the B 2 receptor via sequestration within caveolae, lipid-rich pockets on the surface of endothelial cells. Similarly, Marcic et al. demonstrated that ACE inhibitors enhance the effect of bradykinin at its B 2 receptor by inducing 'crosstalk' between ACE and the receptor [19] .
In vitro and animal studies suggest that the AT 2 receptor provides an additional connection between the RAS and the KKS. During AT 1 receptor blockade, unopposed activation of the AT 2 receptor leads to increased bradykinin, NO and cyclic (c)GMP [11, 20] . Although acute AT 1 receptor blockade does not potentiate the effects of exogenous bradykinin [21] , these data potentially implicate endogenous bradykinin in the beneficial effects of chronic AT 1 receptor blockade [22] .
Bradykinin and antihypertensive effects of ACE inhibitors
The availability of a specific bradykinin B 2 receptor antagonist, icatibant acetate (HOE 140), has allowed investigators to determine the contribution of bradykinin to the effects of ACE inhibitors in vivo. Bradykinin receptor blockade attenuates the hypotensive response to ACE inhibition in rats and dogs [23] [24] [25] . In humans, ACE inhibition enhances [26] whereas B 2 receptor blockade decreases [7, 27] the vasodilator effects of exogenous bradykinin. Studies using icatibant further indicate that endogenous bradykinin contributes to the acute hemodynamic effects of ACE inhibitors in humans. For example, bradykinin receptor blockade decreases the potentiation of endotheliummediated, flow-dependent vasodilation by ACE inhibition in healthy individuals [28] . Similarly, co-administration of icatibant attenuates the acute hypotensive effects of oral captopril in both normotensive and hypertensive subjects [29] .
Bradykinin and antihypertrophic effects of ACE inhibitors
ACE inhibitors decrease cardiac hypertrophy in patients with hypertension [30] . Bradykinin receptor antagonism decreases the antihypertrophic effect of ACE inhibitors in hypertensive animals [23] . Conversely, genetic B 2 receptor deficiency is associated with the development of cardiac hypertrophy [31] . In vitro, bradykinin prevents Ang IIinduced hypertrophy of cultured cardiomyocytes by releasing nitric oxide (NO) from endothelial cells, thereby increasing cardiomyocyte guanosine 3′5′-cyclic monophosphate (cGMP) [32] .
Bradykinin and anti-ischemic and antiatherosclerotic effects of ACE inhibitors
ACE inhibitors reduce the risk of myocardial infarction in patients with decreased left ventricular function [33, 34] , as [49] ).
well as in patients with normal left ventricular function who are at risk for coronary artery disease [35] . Again, studies in animals using icatibant implicate bradykinin in the mechanism of the anti-ischemic effects of ACE inhibitors. Thus ACE inhibition decreases infarct size following coronary artery occlusion in dogs or rabbits and this effect is abolished by either bradykinin receptor antagonism [36, 37] or nitric oxide synthase inhibition with N G -L-nitro-arginine methyl ester (L-NAME) [38] .
Bradykinin, ACE inhibition, and fibrinolytic balance
One mechanism through which bradykinin may contribute to the anti-ischemic effects of ACE inhibitors involves the fibrinolytic system. The endogenous fibrinolytic system serves as one of the major defense mechanisms against intravascular thrombosis. Fibrinolytic activity is regulated by the balance between tPA and PAI-1 ( Fig. 3 ) [39, 40] . Bradykinin stimulates endothelial release of tPA, [8, 42] whereas Ang II increases PAI-1 expression [13] .
Brown et al. [7] have studied the mechanism of bradykinin-induced tPA release from the human vasculature. They demonstrated that bradykinin stimulates vascular tPA release in a dose-dependent manner, that this effect is independent of changes in flow, and that, like vasodilation, this effect is mediated through the bradykinin B 2 receptor. However, following receptor activation, bradykinin appears to cause vasodilation and stimulate tPA release through distinct mechanisms. Thus, while administration of the nitric oxide synthase (NOS) inhibitor L-N G -monomethyl-L-arginine (L-NMMA) attenuates the forearm vasodilator response to bradykinin, indicating that NO contributes to bradykinin-induced vasodilation, L-NMMA alone or in combination with the cyclooxygenase inhibitor indomethacin did not affect the tPA response to bradykinin, suggesting that tPA release is mediated through a NOS-and cyclooxygenase-independent pathway.
ACE inhibitors improve endothelial function as measured by the vasodilator response to endothelium-dependent agonists [42] . ACE inhibition, but not AT 1 receptor blockade, potentiates the effect of exogenous bradykinin on tPA release in the peripheral [41] and coronary vasculature [43] . A recent study using icatibant indicates that ACE inhibition increases constitutive vascular tPA release in subjects at risk for coronary artery disease through effects on endogenous bradykinin [44] .
The findings that bradykinin induces tPA expression and release while Ang II stimulates PAI-1 expression suggest that ACE inhibitors reduce risk of MI, in part, through effects on fibrinolytic balance. Indeed, activation of the renin-angiotensin-aldosterone system by salt depletion or diuretic use increases plasma PAI-1 concentrations, while ACE inhibition significantly decreases plasma PAI-1 without consistently decreasing tPA concentrations [40] . Hence, ACE inhibitors improve the molar ratio of PAI-1 to tPA. These effects have been observed in young normotensive subjects, healthy postmenopausal women, hypertensive subjects, and patients post-MI. For example, in the Healing and Early Afterload Reduction Therapy (HEART) study [45] , ACE inhibition decreased PAI-1 antigen and activity in patients with acute anterior MI. Plasma tPA levels were similar in both the ramipril and control groups. The effect of ACE inhibition on PAI-1 antigen following thrombolysis for acute MI has also been described [46] . ACE inhibition was associated with a diminished rise in PAI-1 antigen following thrombolysis and an increased rate of patency of the infarct-related artery.
The observation that chronic ACE inhibition but not AT 1 receptor antagonism decreases circulating PAI-1 antigen concentrations [47] raises the possibility that bradykinin not only stimulates tPA release, but also contributes to the regulation of PAI-1. Because NO suppresses PAI-1 expression after stimulation by Ang II in aortic smooth muscle cells [48] , it may be hypothesized that bradykinin could moderate PAI-1 expression by releasing NO. Further studies are needed to determine whether bradykinin opposes the effects of Ang II on PAI-1 expression.
Conclusion
Bradykinin favorably alters fibrinolytic balance and promotes release of vasoactive compounds that improve endothelial function. ACE inhibitors potentiate bradykinin by blocking (1) ACE-mediated breakdown of bradykinin, and (2) B 2 receptor desensitization. A substantial body of evidence points to increased local bradykinin action as an important contributing mechanism in the reduction of cardiovascular events [35] .
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